Results 181 to 190 of about 3,252,482 (283)

The Medicine Quality Monitoring Globe: A public health intelligence system for collecting and curating reports of substandard and falsified medical products from publicly available Internet news media. [PDF]

open access: yesPLOS Digit Health
Freifeld CC   +19 more
europepmc   +1 more source

News-bulletin of the Council of Social Agencies, 1942-03

open access: yes, 2020
Indianapolis Council of Social Agencies
core  

Baseline Neuroinflammation Stratifies TSPO‐PET Response to Disease‐Modifying Therapy in Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To investigate which baseline clinical and imaging characteristics best predict TSPO‐PET‐measurable reduction in glial activation following treatment of multiple sclerosis (MS), to utilize this information for designing more efficient biomarker‐based clinical trials targeting glial activation.
Marlene T. Morch   +5 more
wiley   +1 more source

News-bulletin of the Council of Social Agencies, 1941-11

open access: yes, 2020
Indianapolis Council of Social Agencies
core  

Integrated PANoptosis Profiling Identifies Immunosuppressive Subtypes and a Prognostic Signature With Functional Validation of MLKL in Glioblastoma

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The prognosis of glioblastoma (GBM) remains highly unfavorable, largely due to high tumor heterogeneity and an immunosuppressive microenvironment. However, the functional role of PANoptosis in this context is poorly understood. Methods Patients were stratified via K‐means clustering. A risk score model was constructed using prognosis‐
Langfei Tian   +6 more
wiley   +1 more source

News-bulletin of the Council of Social Agencies, 1940-04

open access: yes, 2020
Indianapolis Council of Social Agencies
core  

Disease Course After Anti‐CD20 Discontinuation in Secondary Progressive Multiple Sclerosis—A Multicenter Long‐Term Longitudinal Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To describe long‐term outcomes after anti‐CD20 discontinuation in selected patients with secondary progressive multiple sclerosis (SPMS) who remained without subsequent disease‐modifying therapy (DMT). Methods We retrospectively analyzed data from four centers in Austria and Switzerland.
Ferdinand Otto   +12 more
wiley   +1 more source

Trusted Sources of COVID-19 Vaccine Information by County Characteristics in North Carolina. [PDF]

open access: yesVaccines (Basel)
Staley BT   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy